Adrafinil

Synonyms: CRL 40028
Adrafinil (CRL 40028) 是一种口服有效的觉醒促进剂,可促进中枢去甲肾上腺素能传递,增强自主活动能力、探索行为、辨别学习能力及反应动机,但会损害视觉空间工作记忆,并能拮抗 Prazosin (MS-S85139) 诱导的运动减少和体温降低,发挥抗惊厥作用,诱导皮层高频脑电活动持续增强,可用于警觉性下降和特定认知缺陷等方面的研究。
产品编号: MS-K30198 纯度: 99.59% CAS No.: 63547-13-7 分子式: C15H15NO3S 分子量: 289.35
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Adrafinil (CRL 40028) 是一种口服有效的觉醒促进剂,可促进中枢去甲肾上腺素能传递,增强自主活动能力、探索行为、辨别学习能力及反应动机,但会损害视觉空间工作记忆,并能拮抗 Prazosin (MS-S85139) 诱导的运动减少和体温降低,发挥抗惊厥作用,诱导皮层高频脑电活动持续增强,可用于警觉性下降和特定认知缺陷等方面的研究。

生物实验数据

生物活性 Adrafinil (CRL 40028) is an orally active wakefulness-promoting agent that enhances central noradrenergic transmission, increases locomotor activity, exploratory behavior, discriminative learning ability, and response motivation, while impairing visuospatial working memory; it antagonizes Prazosin (MS-S85139)-induced hypokinesia and hypothermia, exerts anticonvulsant effects, induces sustained enhancement of cortical high-frequency electroencephalographic activity, and can be used in research on decreased alertness and specific cognitive deficits.
体内研究
(In Vivo)

Adrafinil (20 mg/kg; p.o.; 单次给药) 可显著改善衰老比格犬的辨别学习能力,表现为达标所需的错误次数和训练次数减少,且对整体反应潜伏期无显著影响。
Adrafinil (10-20 mg/kg; p.o.; 每日一次共 8 天) 在 20 mg/kg 剂量可通过延迟非匹配位置 (DNMP) 任务中错误次数增加的检测结果,显著损伤老年比格犬的视觉空间工作记忆,而 10 mg/kg 剂量下未使任务表现产生显著变化。
Adrafinil (16 mg/kg; i.p.; 单次给药) 可显著拮抗 Prazosin 诱导的雄性小鼠运动抑制。
Adrafinil (2-8 mg/kg; i.p.; 单次给药) 可在小鼠中对 Prazosin 诱导的低体温产生显著的、剂量依赖性的拮抗作用。
Adrafinil (128 mg/kg; i.p.; 单次给药) 可显著减少 C57BL/6J 震颤小鼠中由处置诱发的惊厥性癫痫发作。
Adrafinil (10-50 mg/kg; p.o.; 单次给药) 可在老年 Beagle 犬中诱导显著的、呈剂量和时间依赖性的旷场运动增加,且不会引发刻板行为。
Adrafinil (10-40 mg/kg; p.o.; 每日一次共 14 天) 可引起老年 Beagle 犬自主活动剂量依赖性增加4]。
Adrafinil (20 mg/kg; p.o.; 单次给药)显著改善老年 Beagle 犬的辨别学习能力及操作动机。

Animal Model: Beagle (5 females, 3 males, 7.5 to 10 years old)
Dosage: 20 mg/kg
Administration: p.o.; single dose; 2 hours before each behavioral test session
Result: Reduced errors to criterion compared to placebo.
Reduced trials to criterion compared to placebo.
Reduced unresponsive trials from 19.2% to 4% in a subject with motivation deficits under placebo.
Did not produce a statistically significant overall effect on response latency.
Animal Model: Beagle (aged, 8 female, 10 male, 9-12 years old)
Dosage: 10 mg/kg; 20 mg/kg
Administration: p.o.; single daily dose; 8 consecutive days
Result: Produced no significant change in error rate compared to placebo at 10 mg/kg.
Significantly impaired visuospatial working memory, with significantly more total errors over the 8-day test period compared to both 10 mg/kg adrafinil and placebo at 20 mg/kg.
Caused impaired performance in both poor and good baseline performer groups at 20 mg/kg, with poor performers exhibiting a significant difference in errors between 10 mg/kg and 20 mg/kg doses.
Did not alter response latency to task stimuli at either dose level.
Animal Model: NMRI (male, 21-23 g)
Dosage: 16 mg/kg
Administration: i.p.; single dose
Result: Restored motor activity to levels significantly higher than prazosin-only treatment.
Animal Model: NMRI (male, 21-23 g)
Dosage: 2 mg/kg; 4 mg/kg; 8 mg/kg
Administration: i.p.; single dose
Result: Restored rectal temperatures to levels significantly higher than prazosin-only treatment.
Produced a significant, dose-dependent antagonism of prazosin-induced hypothermia, with the magnitude of recovery increasing with higher doses.
Animal Model: C57BL/6J quaking (male or female, 20-22 g, handling-induced convulsive seizures model)
Dosage: 128 mg/kg (seizure reduction); 16 mg/kg, 32 mg/kg, 64 mg/kg (no effect)
Administration: i.p.; single dose
Result: Reduced mean seizure count from 10.9 before treatment to 2.2 after treatment.
Failed to produce a significant reduction in seizure counts at doses of 16, 32, and 64 mg/kg.
Had its protective effect against seizures clearly antagonized by co-administration of prazosin.
Animal Model: Beagle dogs (both sexes, 7 years of age or older)
Dosage: 10 mg/kg; 30 mg/kg; 50 mg/kg
Administration: p.o.; single dose
Result: Produced a significant increase in locomotion relative to placebo, with effects that were dose-dependent and time-dependent.
Decreased urination frequency significantly only at the 50 mg/kg dose.
Induced no stereotypical behavior.
Animal Model: Beagle dogs (9 to 16 years of age)
Dosage: 10 mg/kg; 20 mg/kg; 30 mg/kg; 40 mg/kg
Administration: p.o.; daily; 14 consecutive days
Result: Reliably increased locomotor activity at doses of 20, 30, and 40 mg/kg, with effects that were dose-dependent.
Generally induced no stereotypical behavior, though some individual dogs showed no response or decreased locomotion.
Decreased urination frequency only at the 40 mg/kg dose.
Caused a dose-dependent increase in serum levels at 2 hours post-dosing; at 10 hours, 40 mg/kg group levels were lower than the 10 mg/kg group (non-significant).
Dogs that showed increased activity had higher serum levels at 2 hours post-treatment and lower levels at 10 hours compared to non-responders.
Animal Model: Beagle dogs (7 to 10 years of age)
Dosage: 20 mg/kg
Administration: p.o.; single dose prior to testing
Result: Significantly improved discrimination learning performance relative to placebo, with fewer errors and fewer trials to reach criterion.
Improved performance motivation and reduced day-to-day response variability in one dog with response failures under placebo.
Animal Model: Beagle dogs (over 10 years of age)
Dosage: 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: p.o.; daily; 3 consecutive days; 8 consecutive days
Result: Induced an arousal-type EEG state in all three dogs, characterized by increased alpha and beta activity and decreased delta and theta activity, with effects lasting for 4 hours post-administration.
Showed no differences in EEG effects between the 10, 20, and 40 mg/kg doses.
Caused a greater increase in alpha and beta activity in dogs with baseline EEG dominated by lower frequencies (delta, theta) than dogs with higher baseline alpha/beta activity.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 289.35
分子式 C15H15NO3S
CAS No. 63547-13-7
别名 CRL 40028

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (345.60 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.4560 mL17.2801 mL34.5602 mL86.4006 mL
5 mM0.6912 mL3.4560 mL6.9120 mL17.2801 mL
10 mM0.3456 mL1.7280 mL3.4560 mL8.6401 mL
15 mM0.2304 mL1.1520 mL2.3040 mL5.7600 mL
20 mM0.1728 mL0.8640 mL1.7280 mL4.3200 mL
25 mM0.1382 mL0.6912 mL1.3824 mL3.4560 mL
30 mM0.1152 mL0.5760 mL1.1520 mL2.8800 mL
40 mM0.0864 mL0.4320 mL0.8640 mL2.1600 mL
50 mM0.0691 mL0.3456 mL0.6912 mL1.7280 mL
60 mM0.0576 mL0.2880 mL0.5760 mL1.4400 mL
80 mM0.0432 mL0.2160 mL0.4320 mL1.0800 mL
100 mM0.0346 mL0.1728 mL0.3456 mL0.8640 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础